Pharma Journalist -

Roivant Sciences and ArQule announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater…
Read More...

Xcovery announced the initiation of its Phase 2 clinical trial of ensartinib (X-396), the company’s lead anaplastic lymphoma kinase (ALK) drug candidate, in patients with advanced…
Read More...

Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational cell therapy for the treatment of Duchenne muscular…
Read More...

ORICULA THERAPEUTICS, LLC., a biotech company introducing medications to preserve hearing and balance, announced FDA permission to begin volunteer human testing for safety,…
Read More...

NetVation DL Medicine announced that it has entered into a two-year research collaboration with Pfizer Inc (NYSE: PFE). Under the terms of the agreement, DL Medicine will screen and…
Read More...

Liquidia Technologies announced the appointment of Kevin Gordon as President and Chief Financial Officer. Mr. Gordon will oversee finance operations and strategy, corporate development…
Read More...

Veeva Systems announced that specialty pharmaceutical company EVER Pharma adopted Veeva OpenData and Veeva CRM to empower its growing team in Poland with the accurate customer data…
Read More...

Shield Therapeutics plc announces top-line results from its AEGIS-CKD pivotal Phase III study of Feraccru. Feraccru is a novel oral ferric iron therapy that has been approved and…
Read More...

Teva Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for fremanezumab, an anti-calcitonin gene-related…
Read More...

Allergan plc announced that Matthew M. Walsh has been appointed Executive Vice President and Chief Financial Officer. He will formally join Allergan later this month following a…
Read More...